Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The rationale for this pharmacokinetic (PK) study is to determine the PK parameters for Lu AA21004 (Vortioxetine) in the Chinese population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women

NCT02386488

Pharmacokinetics

COMPLETED PHASE1

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

NCT02170220

Severe Hepatic Impairment

COMPLETED PHASE1

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

NCT04667156

Healthy Volunteers

COMPLETED PHASE1

Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male

NCT07166887

Healthy Subjects

COMPLETED PHASE1

A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers

NCT01433575

Healthy Volunteer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lu AA21004

Group Type EXPERIMENTAL

Lu AA21004

Intervention Type DRUG

10 mg immediate-release (IR), one single dose, orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lu AA21004

10 mg immediate-release (IR), one single dose, orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vortioxetine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is a Chinese man or woman
* The subject is, in the opinion of the investigator, generally healthy
* If female, the subject must have a negative pregnancy test at screening and baseline, and agree not to try to become pregnant from Screening until after the Follow-up Visit